Outcome Exposure | N (%) | Crude OR†(95% CI) | Adjusted OR ††(95% CI) | |
---|---|---|---|---|
Six months | Â | Â | Â | Â |
   Virologic failure | 30 mg | 44 (4.2%) | 1 | 1 |
 | 40 mg | 133 (7.6%) | 1.86 (1.31-2.64) | 1.69 (0.81-3.52) |
   Stavudine discontinuation | 30 mg | 60 (4.1%) | 1 | 1 |
 | 40 mg | 135 (5.5%) | 1.37 (1.00-1.87) | 0.87 (0.45-1.71) |
   Peripheral neuropathy | 30 mg | 31 (2.1%) | 1 | 1 |
 | 40 mg | 220 (9.0%) | 4.57 (3.12-6.70) | 3.17 (1.71-5.90) |
Twelve months | Â | Â | Â | Â |
   Virologic failure | 30 mg | 58 (5.0%) | 1 | 1 |
 | 40 mg | 208 (10.6%) | 2.27 (1.68-3.06) | 1.62 (0.88-2.97) |
   Stavudine discontinuation | 30 mg | 158 (10.8%) | 1 | 1 |
 | 40 mg | 413 (16.9%) | 1.68 (1.38-2.05) | 1.71 (1.13-2.57) |
   Peripheral neuropathy | 30 mg | 41 (2.8%) | 1 | 1 |
 | 40 mg | 357 (14.6%) | 5.94 (4.27-8.26) | 3.12 (1.86-5.25) |
   Lipoatrophy | 30 mg | 4 (0.3%) | 1 | 1 |
 | 40 mg | 81 (3.3%) | 12.5 (4.6-34.2) | 11.8 (3.2-43.8) |
   Hyperlactemia/lactic acidosis | 30 mg | 15 (1.0%) | 1 | 1 |
 | 40 mg | 179 (7.3%) | 7.64 (4.49-12.99) | 8.37 (3.83-18.29) |